Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmented BFM Therapy for AYA ALL/LL
NCT00866749Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2006
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daunorubicin, vincristine sulfate liposome injection, pegaspargase, methotrexate, cyclophosphamide and 4 more in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Event-Free Survival at 3 years, Overall Survival at 12 years and 1 more. Started Sep 2006; status: completed.
02
Drugs
daunorubicinvincristine sulfate liposome injectionpegaspargasemethotrexatecyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00866749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866749.